Spondyloarthritis 2017

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

By

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Etanercept for Spondyloarthritis: Impact on Disease Progression

Etanercept for Spondyloarthritis: Impact on Disease Progression

By

The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.

Secukinumab Long-Term Reduction of Radiographic Progression in Ankylosing Spondylitis

Secukinumab Long-Term Reduction of Radiographic Progression in Ankylosing Spondylitis

By

For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

By

Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.

Role of Gut Microbiota, Host Genetics in Reactive Arthritis

Role of Gut Microbiota, Host Genetics in Reactive Arthritis

By

Researchers found that HLA status was associated with gut microbiota diversity.

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

By

The guideline includes recommendations for treating adult patients with active psoriatic arthritis.

TNF Inhibitors Decrease Extraarticular Manifestations in Ankylosing Spondylitis

TNF Inhibitors Decrease Extraarticular Manifestations in Ankylosing Spondylitis

By

Treatment with TNF inhibitors has led to improvement in physical function and quality of life in patients with ankylosing spondylitis.

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

By

Results from phase 3 trials OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) presented at the American College of Rheumatology 2017 in San Diego, California.

Local Inflammation Predicts Structural Damage in Axial Spondyloarthritis

Local Inflammation Predicts Structural Damage in Axial Spondyloarthritis

By

Researchers recruited patients with recent onset axial spondyloarthritis and conducted MRI of the spine or MRI of the sacroiliac joints at baseline, 2 years, and 5 years.

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

By

Researchers observed a higher prevalence of psychiatric disorders among female patients with psoriatic arthritis.

Secukinumab Effectively Inhibits Radiographic Progression of PsA

Secukinumab Effectively Inhibits Radiographic Progression of PsA

By

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

By

Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

By

Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.

Novel Interleukin Inhibitors Efficacious for Psoriatic Arthritis

Novel Interleukin Inhibitors Efficacious for Psoriatic Arthritis

By

Inhibitors of interkeukins 6, 12, 23 and 17A were shown to be effective and generally well-tolerated agents for the treatment of psoriatic arthritis.

Biomarkers of Peripheral and Axial Arthritis in Psoriatic Disease

Biomarkers of Peripheral and Axial Arthritis in Psoriatic Disease

By

Study confirms the validity of previously identified bone-turnover biomarkers for psoriatic disease-associated arthritis and for axial arthritis.

Etanercept May Slow Radiographic Sacroiliac Joint Progression in Axial Spondyloarthritis

Etanercept May Slow Radiographic Sacroiliac Joint Progression in Axial Spondyloarthritis

By

In patients with recent-onset axial spondyloarthritis (axSpA), the long-term use of etanercept may result in a lower rate of radiographic progression in the sacroiliac joint.

TNF Blockers and Reduced Spinal Radiographic Progression in Ankylosing Spondylitis

TNF Blockers and Reduced Spinal Radiographic Progression in Ankylosing Spondylitis

By

TNFi therapy in ankylosing spondylitis has a clinically relevant inhibitory effect on spinal radiographic progression.

Psoriatic Arthritits Patients Maintain Clinical Improvement With Long-Term Secukinumab

Psoriatic Arthritits Patients Maintain Clinical Improvement With Long-Term Secukinumab

By

Results from the FUTURE 2 study show that secukinumab improves signs and symptoms in patients with active psoriatic arthritis through 2 years of therapy.

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

By

Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.

Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs

Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs

By

HBV reactivation rates were lower among all chronic HBV infection patients on antiviral prophylaxis, regardless of whether they were receiving TNF inhibitors.

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

By

The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk

Axial Spondyloarthritis Classification: Assessing Need for Spine MRI

Axial Spondyloarthritis Classification: Assessing Need for Spine MRI

By

Researchers recommended against including MRI in the Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis.

No Association Between Postop Opioid Intake and Patient Satisfaction After Ankle Fracture

No Association Between Postop Opioid Intake and Patient Satisfaction After Ankle Fracture

By

To improve pain relief, surgeons should proactively address stress, distress, and ineffective coping strategies.

Nonradiographic Axial Spondyloarthritis May Be Revealed by MRI

Nonradiographic Axial Spondyloarthritis May Be Revealed by MRI

By

A study analyzes whether underlying sacroiliac erosions may be present in patients with nonradiographic axial spondylarthritis who have normal radiographs.

Ultrasound-Detected Synovitis Predicts Short-term PsA Disease Flare

Ultrasound-Detected Synovitis Predicts Short-term PsA Disease Flare

By

The ability of Power Doppler Ultrasound to predict short-term psoriatic arthritis disease flare was investigated in a new study.

Psoriatic Arthritis, Cardiovascular Health Improved With Etanercept Therapy

Psoriatic Arthritis, Cardiovascular Health Improved With Etanercept Therapy

By

The researchers noted that the small changes in lipid profile do not account for the cardiovascular benefits seen in patients taking etanercept.

Markers of Radiographic Spinal Progression in Ankylosing Spondylitis

Markers of Radiographic Spinal Progression in Ankylosing Spondylitis

By

Serum leptin and high molecular weight adiponectin have an inverse relationship with radiographic spinal progression in patients with ankylosing spondylitis.

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

Early Predictors of Poor Long-Term Treatment Response in Spondyloarthritis

By

Determining which patients are unlikely to respond to therapy early on may help reduce unnecessary treatment and contain costs.

Serum Amyloid A Levels May Act as Biomarker for Disease Activity in Psoriatic Arthritis

Serum Amyloid A Levels May Act as Biomarker for Disease Activity in Psoriatic Arthritis

By

Repeated serum amyloid A measurements could act as an additional marker for monitoring disease activity over time in patients with psoriatic arthritis.

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

By

Ixekizumab was found to benefit patients with psoriatic arthritis showing poor response to conventional treatment when administered over a 2- or 4-week period.

Sign Up for Free e-newsletters